Overview

Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Flumazenil